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Marianna Purgato1,2*, Clive Adams1 and Corrado Barbui2Abstract
Objective: To quantify schizophrenia trialling activity in African countries and to describe the main features of
these trials.
Methods: We searched the Cochrane Schizophrenia Group Register, which contains 16,000 citations to 13,000
studies relating only to people with schizophrenia or schizophrenia-like illness, to identify schizophrenia trials
conducted in Africa without time limitation.
Results: A total of 38 trials met the inclusion criteria and were included in our analysis. Of the 54 countries of
Africa, only 8 produced at least one trial: South Africa produced the majority of trials (20 out of 38 trials, 53%),
followed by Nigeria (7 out of 38 trials, 18%) and Egypt (4 out of 38 trials, 11%). The majority of studies investigated
the efficacy of pharmacological interventions, were short in duration, and employed a double-blind design. The
quality of reporting was generally poor. We found six trials comparing antipsychotics from the WHO Essential List of
Medicine versus new generation antipsychotics. In terms of efficacy and acceptability, these studies failed to show
any advantage of newer antipsychotics over first-generation agents.
Conclusions: We observed an impressive mismatch between the number of individuals with schizophrenia living
in African countries, estimated to be around 10 million, and the overall number of patients included in African trials,
which is less than 2,000. These few trials were of low quality and appeared not to reflect the real needs of the
population. We argue that the concept of pragmatism should be introduced into the design of randomized trials in
African countries. Pragmatic trials should investigate whether treatments, given in real-world circumstances, really
have clinically meaningful effects.
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Most of the global burden of mental illness falls to the
poorest nations, where 80% of world’s population live
[1]. Africa is the second-most-populated continent, with
around 1 billion people, or 15% of the world's popula-
tion. For schizophrenia, a major psychiatric disorder that
affects about 0.5% of world population [2], it has been
estimated that between 4 and 5 million individuals
afflicted by these severe psychiatric disorders live in Af-
rican countries [2]. Despite these impressive numbers,* Correspondence: marianna.purgato@univr.it
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reproduction in any medium, provided the orthe worldwide deficit of research about psychiatric disor-
ders is particularly acute in low- and middle-income
countries (LAMICs), including several African countries
[3]. LAMICs devote less than 1% of their health expend-
iture to mental health and have poorly developed mental
health policies and research infrastructures [4].
For patients, carers and policymakers local data are
important. Even well-conducted trials, if undertaken in a
very dissimilar care-culture may be difficult to apply.
Local trials are important and informative whether they
agree or disagree other similar studies from afar. All evi-
dence must be considered but the local perspective not
ignored. The quality of any trialling activity is another
crucial issue, as it may vary across nations [5,6]. Forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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China has been considered in many surveys and quality
remains a major concern [7-11]. Elsewhere it has been
shown that pioneering mental health trials from LAMICs
are of as mixed quality as their more accessible counter-
parts from richer nations, but cannot be identified in com-
monly used bibliographic databases [12].
The Cochrane Schizophrenia Group produces and
maintains a register of all studies [13]. This involves
regular and systematic searching of 71 databases world-
wide. The studies identified in this way are reliably
indexed by country.
The aim of this work is to quantify schizophrenia trial-
ling activity in African countries and to provide detailed
information on the main clinical and methodological fea-
tures of these trials. Our analysis could be used by
researchers and policy makers to help plan future research
to cover the mental health needs of African population.
Methods
Search methods for identification of studies
We searched the Cochrane Schizophrenia Group Regis-
ter to identify any trial conducted in Africa without time
limitation. The Cochrane Schizophrenia Group Register
contains 16,000 citations to 13,000 studies relating only
to people with schizophrenia or schizophrenia-like ill-
ness [13]. The register includes all published and unpub-
lished references to randomized, quasi randomized and
controlled clinical trials without language restrictions.
These studies are indexed regarding the country of ori-
gin, the interventions under study and the number of
participants. The last version of register was February
2012.
Types of studies
We included all randomised controlled trials and con-
trolled clinical trials undertaken in any African country.
Included studies compared any pharmacological and
non-pharmacological treatments with other active treat-
ments or placebo. Only studies that enrolled patients in
Africa were considered. Multicentre studies were
included only if all centres enrolling patients were
located in Africa.
Types of participants
Participants were in- and out-patients of both sexes,
with a primary diagnosis of schizophrenia and related
psychotic disorders, according to the criteria described
in the DSM, ICD, or according to any other clinical or
standardized criteria.
Selection of trials
Included and excluded studies were collected following
the Preferred Reporting Items for Systematic reviewsand Meta-Analyses – PRISMA flow diagram [14]. From
the Cochrane Schizophrenia Group Register we extracted
all records corresponding to studies carried out in Africa.
We examined all titles and abstracts, and obtained full
texts if the word “random” or “randomised” or “control”
or “controlled” was present in the title and/or abstract.
MP and CB read the full texts, determined whether they
met inclusion criteria and extracted the data. Considerable
care was taken to exclude duplicate publications.
Assessment of risk of bias in included studies
For quality assessment we used the Cochrane risk-of-
bias tool (Oxford, England, Cochrane Collaboration).
This instrument consists of seven items [15]. Two of the
items assess the strength of the randomization process
in preventing selection bias in the assignment of partici-
pants to interventions: adequacy of sequence generation
and allocation concealment. The third and fourth items
assess the influence of performance bias and detection
bias on the study results. The fifth item assesses the like-
lihood of incomplete outcome data, which raise the pos-
sibility of bias in effect estimates. The sixth item assesses
selective reporting, the tendency to preferentially report
statistically significant outcomes. This item requires a
comparison of published data with trial protocols, when
such are available. The final item refers to other sources
of bias that are relevant in certain circumstances, such
as, for example, sponsorship bias.
Data extraction
The following information was extracted using an elec-
tronic spreadsheet: year of publication, geographic area
(country of Africa), type of experimental and control
intervention, sample size, weeks of follow-up, diagnostic
criteria, number of outcome measures, Gross Domestic
Product (GDP) at the time when each study was carried
out. For studies that compared antipsychotics included
in the WHO Essential List of Medicines [16] with new
generation antipsychotics we additionally extracted effi-
cacy and acceptability data. For efficacy data, the mean
change from baseline to endpoint, or the mean scores at
endpoint, at the Brief Psychiatric Rating Scale (BPRS) or
Positive and Negative Syndrome Scale (PANSS) were
extracted, together with the standard deviation (SD) or
standard error (SE) of these values, and the number of
patients included in these analyses. For acceptability
data, the number of patients leaving the study early for
any reason was extracted.
Data presentation
We calculated simple percentages (%). To ascertain
whether sample size and number of efficacy measures
have increased in the last 40 years, we used a box plot
diagram and a nonparametric test for trend (extension
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compared antipsychotics included in the WHO Essential
List of Medicines with new generation antipsychotics, ef-
ficacy and acceptability data were entered and analyzed
using the Cochrane Collaboration’s Review Manager soft-
ware version 5.1 (Oxford, England, Cochrane Collabor-
ation). Continuous data were analyzed using standardized
mean differences (SMDs) with the random-effects-model
(with 95% confidence intervals [CI]); for dichotomous out-
comes, the odds ratio (OR) was calculated based on the
random effects model (with 95% CI). This approach was
used to present the results of individual studies, but no
overall treatment estimates were calculated.
Results
Characteristics of included studies
The original search yielded 69 records, of which 27 were
excluded because ineligible or not relevant. The remaining











































Figure 1 PRISMA Flow diagram.met the inclusion criteria and were included in our ana-
lysis (Figure 1) (for references of included studies, see
reference list from [17-54]).
Eight out of the 54 countries of Africa produced at
least one trial (Figure 2). South Africa produced the ma-
jority of trials (20 out of 38 trials, 53%), followed by
Nigeria (7 out of 38 trials, 18%) and Egypt (4 out of 38
trials, 11%). These countries had the highest Gross Do-
mestic Product compared with the other countries pro-
ducing trials in Africa (Figure 2). The characteristics of
all included studies are presented in Table 1. The major-
ity of studies investigated pharmacological interventions,
with a drug versus drug design in most cases (33 out of
38 trials, 87%). Most studies were short in duration (22
out of 38 had a follow-up ≤ 12 weeks, 58%), had a
double-blind design and used standardized diagnostic
criteria (DSM or ICD). Local ethics committee approval
has been mentioned in 22 out of 38 studies. Fifteen stud-


















Figure 2 Distribution of schizophrenia trials by African country and Gross Domestic Product.
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remaining 20 studies the role of sponsorship was unclear
(Table 1).
While sample size only minimally increased over time
(Figure 3), as shown by Spearman's rank correlation co-
efficient (rho = 0.333; p= 0.043), the number of outcomes
measures significantly increased over time (rho = 0.357;
p< 0.027).Risk of bias
The standard of reporting was generally poor (Figure 4)
(For study by study risk of bias, see Additional file 1).
The generation of the randomization sequence and the
concealment of allocation were not properly described
in the majority of studies. Blinding was adopted in some
studies, but not accurately described. The risk of other
bias, such as sponsorship bias, could not be excluded, as
several studies received financial support from pharma-
ceutical industries.Essential antipsychotics versus new generation
antipsychotics
Six trials compared antipsychotics from the WHO es-
sential list of medicine versus new generation antipsy-
chotics. Essential antipsychotics were haloperidol and
chlorpromazine; new generation antipsychotics werequetiapine, olanzapine and risperidone. Efficacy and ac-
ceptability data, available for 5 studies only, are pre-
sented in Figures 5 and 6, respectively. In terms of
efficacy, three studies comparing haloperidol versus new
generation antipsychotics failed to show any difference.
Studies comparing chlorpromazine versus olanzapine
provided contrasting evidence. In one study chlorpro-
mazine was less effective than olanzapine (SMD=1.55,
95% CI 0.78 to 2.32 n = 39), in the other one chlorpro-
mazine was slightly more effective than olanzapine
(SMD −0.58, 95% CI −1.24 to 0.08 n = 41) (Figure 5). In
terms of acceptability, studies failed to show any differ-
ence (Figure 5).Discussion
To our knowledge, this is the first survey investigating
content and quality of schizophrenia trials carried out in
African countries. A first impressive result is the mis-
match between the number of individuals with schizo-
phrenia living in African countries, estimated to be
around 5 million [2], and the overall number of patients
included in African trials, which is less than 2,000
(accounting for 0.001% of patients included in the total-
ity of trials conducted in schizophrenia at a global level
according to the Cochrane Schizophrenia Register)
(http://szg.cochrane.org/cochrane-schizophrenia-group-
Table 1 Characteristics of schizophrenia trials conducted
in Africa
STUDIES (n=38) No %
Type of comparison
Typical AP versus typical AP 12 (31.58)
Typical AP versus placebo 3 (7.89)
Typical AP versus no treatment 1 (2.63)
Typical AP versus atypical AP 6 (15.79)
Atypical AP versus atypical AP 4 (10.53)
Other pharmacological interventions 7 (18.42)











Two arms 34 (89.47)
Three arms or more 4 (10.53)
Weeks of follow-up
< 6 weeks 16 (42.43)
6–12 weeks 9 (24.24)
13–24 weeks 7 (18.18)
> 24 weeks 6 (15.15)
Blinding
Open label 6 (15.79)
Single blind 7 (18.42)




DSM†− ICD†† 25 (65.79)










Table 1 Characteristics of schizophrenia trials conducted
in Africa (Continued)
Yes 15 (39.48)
Independent study 3 (7.89)
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if one considers that 15% of the world population lives
in Africa, but only 0.005% of the world schizophrenia
trials have been conducted in the continent (Figure 7).
As one might expect, the great majority of trials on
schizophrenia are conducted in high-income countries
(32% in North America and 26% in Europe), but emer-
gent countries like China, Brazil or India –with a
middle-low or low Gross Domestic Product- are having
a recent burgeoning of work [6]. For example, even if
Chinese trials are often described as poor in methodo-
logical quality [9,55], China produced in the last decade
a great amount of randomized trials (22% of all schizo-
phrenia trials coded in the Cochrane Schizophrenia
Group Register come from China) [6]. Also from Brazil
and India there are examples of emergent high quality
research activity [56].
A second issue is that these few trials appear not to re-
flect the real needs of the population. The World Mental
Health surveys showed that more than 75% of those
identified with serious mental disorders in LAMICs
received no care at all, despite substantial role disability
[57]. In sub-Saharan Africa, the treatment gap for
schizophrenia and other psychoses has been shown to
exceed 90%. Additionally, even where treatment is pro-
vided, it often is far below minimum acceptable stan-
dards. In such a situation it seems difficult to believe
that trials addressing the efficacy of antipsychotic drugs
versus placebo, or trials aiming to ascertain the added
value of new generation antipsychotics over inexpensive
“essential” antipsychotics can be seen as a priority. If one
additionally considers that most trials were underpow-
ered, failed to report basic methodological details such
as, for example, information about the methods of ran-
dom allocation, and its concealment from the study
investigators, or how blinding was preserved, than the
overall situation seems even more desolating, as the
practical contribution of these studies to African patients,
carers and policymakers is at least questionable. Unfortu-
nately, trial quality has not substantially increased over
time: while sample size increased only minimally over
time, patient selection criteria and outcome assessments
have become much more sophisticated, as suggested by
the increase in use of standardized diagnostic criteria and
by the steadily increase in the number of outcome mea-
sures. Although this trend may have increased the internal
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Figure 3 Distribution of schizophrenia trials carried out in Africa by sample size (a) and number of outcome measures (b) from 1970
to 2010. The horizontal line represents the median, the box extends to cover the interquartile range and the vertical line extends to the
extremes.
Figure 4 Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages
across all included studies.
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Favours first generation APs Favours new generation APs 
Chlorpromazine 
Haloperidol New generation APs 
New generation APs 
Figure 5 Efficacy data of schizophrenia trials conducted in Africa comparing antipsychotics included in the WHO List of Essential
Medicines (haloperidol and chlorpromazine) with new generation antipsychotics.
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This increasing drift from real world practice makes it dif-
ficult to apply trial results to typical patients [58]. Simi-
larly, we observed that the number of outcome measures
has increased during the last 40 years. This confusion of
measuring suggests, at the very least, a lack of consensus
on what is important.
Instead of increasing the drift from real world
practice, randomized trials should be able to enroll
real-world patients populations to be followed under
real-world circumstances and assessed with outcome
measures that are used in practice. As has already been
happening in many other countries of the world, the
concept of pragmatism should be introduced into the
design of randomized trials in African countries. Prag-
matic trials should investigate whether treatments,
given in real-world circumstances, really have clinically
meaningful effects. An example of this attitude is theHaloperidol Newgeneration APs
Chlorpromazine New generation APs
Figure 6 Acceptability data (total dropout rates) of schizophrenia tria
WHO List of Essential Medicines (haloperidol and chlorpromazine) wiseries of TREC studies carried out in Brazil and India
which randomized treatments given in day to day prac-
tice, left all subsequent decisions to clinicians, and used
routine data as primary outcomes [59-62]. The concept
of pragmatism could be similarly applied to the purpose
of clinical trials, with a strong focus and commitment
to answering questions of high public health relevance.
Examples of trials undertaken with this logic are avail-
able, for example in the area of interventions for psy-
chosocial wellbeing in humanitarian settings [63].
Another pragmatic area of interest is implementation
science [64], with a focus on investigating the most ef-
fective interaction between specialist and non-specialist
care providers, such as the extent to which tasks can be
shifted and the duration, type, and frequency of training
and supervision that are required. WHO has recently
produced an evidence-based intervention package with
recommendations to facilitate care at first and secondFavours first generation APs Favours new generation APs
ls conducted in Africa comparing antipsychotics included in the
th new generation antipsychotics.
7%
of the world population with schizophrenia lives in Africa
(5 million/70 million)
0.005%
of the world schizophrenia trials have been done in 
Africa (69/13,542)
0.001%
of the patients entered in 
schizophrenia trials worldwide 
have been enrolled in Africa 
(4,108/1,347,816)
Figure 7 Pyramid describing the mismatch between the number of individuals with schizophrenia living in African countries and the
number of trials conducted, and patients involved, in African countries.
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ders in low and middle income countries [65,66], but
no randomized evidence exists on how this package
should be implemented to maximize benefit at sustain-
able costs. Researchers and funders have tremendous
responsibility in this context. Consortia and networks,
advocacy organizations, universities and their partners
should organize their activities considering that the im-
plementation of a new generation of randomized trials
in African countries is a pressing priority [64].
The present analysis has limitations. First, we did not
include international multicentre studies where African
countries were single sites, possibly loosing studies with
good sample sizes and potentially better reporting. Sec-
ond, despite the extensive searches, the possibility that
some relevant studies have not been identified cannot be
ruled out. The Cochrane Schizophrenia Group maintains
a trial register by regularly and systematically searching
71 databases worldwide. However, it is possible that
some journals are not indexed in these databases, and
there might be some other local databases that are not
included in our searches. Other factors are that some
databases have become available only recently, and poor
indexing within some databases may have impaired re-
trieval. We argue that accessibility to trials conducted in
African countries should be improved by prospective
registration of all future trials, as endorsed by the Inter-
national Committee of Medical Journal Editors (ICMJE)
[67] and the World Health Organization's International
Clinical Trials Registry Platform [68].
In conclusion, this study generates information on
the clinical and methodological characteristics of trialsconducted in Africa on schizophrenia interventions.
This information is needed to plan and implement fu-
ture schizophrenia clinical trials, to suggest research
areas that may have not received adequate attention,
and to point to methodological aspects that need to
be addressed when planning future trialling activities.
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